Thus, the serum values of hepatic dysfunction markers (AST and ALT) and hepatobiliary disease markers (alkaline phosphatase (ALP) and total bilirubin (T-BIL)) in mild, moderate, and severe COVID-19 patients (without active liver disease) were examined (Figs. 4A, S10A and B). This evidence concerns the gene GPT and COVID-19.